Compare CSTE & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | ITRM |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 24.3M |
| IPO Year | 2012 | 2018 |
| Metric | CSTE | ITRM |
|---|---|---|
| Price | $1.10 | $0.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 03-04-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.14 |
| 52 Week High | $3.26 | $1.42 |
| Indicator | CSTE | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 35.43 |
| Support Level | $0.86 | $0.14 |
| Resistance Level | $2.00 | $0.39 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 60.27 | 41.83 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.